BioXcel Therapeutics, Inc. news
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 1:45 p.m. Eastern Time. Management will discuss the Co
- SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use
- Top-line pivotal data expected in 1H 2023
- Estimated 23 million annual agitation episodes in the home-setting would more than double current market opportunity for BXCL501 in the U.S. 1-4
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 2:30 p.m. Eastern Time. Management will discuss
- Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment
- Over 142 million opioid prescriptions dispensed in the U.S. in 20201
- More than 1.7 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers in 20161
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizi
- Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023
- Phase 3 TRANQUILITY III study underway with patient enrollment initiating in H2 2022
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the first patient has been dosed in the Phase 3 TRANQUILITY II study